Lirentelimab (AK002) is a humanized Completely prevented passive systemic anaplaxis (PSA) as shown by a lack of change in rectal temperature and symptom scores in mice.
[1]. Youngblood BA, et al. AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaplaxis in Mice. Int Arch Allergy Immunol. 2019;180(2):91-102.